SCHEMBL20154483

SCHEMBL20154483

CCC(C)N1CC2CC(C1)N2C(=O)C1CCOCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.45
CCR2 P41597 4/20 0.37
CACNA1G O43497 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNA1I Q9P0X4 1/20 0.34
RET P07949 1/20 0.34
HRH3 Q9Y5N1 2/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PKM P14618 1/20 0.33
AXL P30530 1/20 0.32
FLT3 P36888 1/20 0.32
TYRO3 Q06418 1/20 0.32
MERTK Q12866 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22030752 0.88 RECQL (0.44) CCR2TSHRALDH1A1MEN1KMT2A
SCHEMBL20070420 0.85 PIK3CD (0.49) PIK3CDCCR2CACNA1GCACNA1HCACNA1I
SCHEMBL20160411 0.81 PIK3CD (0.41) PIK3CDCCR2CACNA1GCACNA1HCACNA1I
SCHEMBL22030592 0.81 RET (0.35) PIK3CDCCR2RETALDH1A1
SCHEMBL22031247 0.79 PIK3CD (0.44) PIK3CDCCR2CACNA1GCACNA1HCACNA1I
SCHEMBL20154481 0.77 PIK3CD (0.40) PIK3CDCCR2RETHRH3
SCHEMBL20071302 0.75 HRH3 (0.40) PIK3CDCCR2HRH3HPGDMAPT
SCHEMBL22031248 0.75 PIK3CD (0.41) PIK3CDCCR2CACNA1GCACNA1HCACNA1I
SCHEMBL20160410 0.74 PIK3CD (0.39) PIK3CDCCR2RETHRH3
SCHEMBL20148605 0.74 RECQL (0.47) CCR2HRH3TSHRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF PIK3CD 1191/4885CCR2 1878/4885CACNA1G 4361/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF PIK3CD 1191/4885CCR2 1878/4885CACNA1G 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.